ArticleClinical nutrition research2026
Effects of propolis supplementation on blood glucose and lipid profiles in individuals with metabolic syndrome and type 2 diabetes: a systematic review and meta-analysis.
Article in Clinical nutrition research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePropolis has been suggested as a complementary therapy for improving glycemic control and lipid metabolism. However, evidence from clinical trials remains inconsistent. This systematic review and meta-analysis aimed to provide a clear and updated assessment of the effects of propolis supplementation on fasting blood sugar (FBS) and lipid profiles in individuals with type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS).
methodsA comprehensive search was conducted on the PubMed, Scopus, Cochrane Library, and Web of Science databases through December 2024 to identify randomized controlled trials (RCTs) evaluating the impact of propolis supplementation on FBS and lipid parameters. Eligible data were pooled using a random-effects model, and weighted mean differences (WMDs) were calculated as pooled effect sizes.
resultsA total of 12 RCTs were included, encompassing 736 participants. Propolis supplementation significantly reduced FBS (WMD, -12.08 mg/dL; 95% confidence interval [CI], -19.13 to -5.04; P=0.001) and triglyceride (TG) levels (WMD, -25.40 mg/dL; 95% CI, -44.21 to -6.59; P=0.008) without significantly affecting the levels of total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol.
conclusionThese findings suggest that propolis supplementation may modestly improve glycemic control and reduce TG levels in individuals with T2DM and MetS. However, the limited number of available studies and relatively small sample sizes highlight the need for large, high-quality RCTs to verify these findings and clarify the metabolic effects of propolis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.